On December 9-11, Russia as a Leader in the Fight against Tuberculosis: New Approaches and Technologies, a nationwide research-to-practice conference, was held.

In addition to anti-tuberculosis activities management in the context of the COVID-19 pandemic, prospects for the treatment of patients with novel coronavirus infection, and innovations in the treatment of pulmonary tuberculosis, the conference also discussed effectiveness of combination anti-tuberculosis drugs manufactured by Pharmasyntez.

Making a report at the Innovations in the Treatment of Pulmonary Tuberculosis Symposium, S.S. Shilovsky highlighted problems associated with the treatment of patients in the institutions of the Directorate of the Federal Penitentiary Service. He presented complex clinical cases where Perchlozone was used which resulted in the recovery of patients with multidrug-resistant (MDR) TB after 18 months of therapy.

Solutions for using Perchlozone to alleviate adverse events in patients with MDR and XDR TB were presented at the Problems of Treating Patients with MDR and XDR TB: Prospects for Chemotherapy of Drug-Resistant Tuberculosis, a satellite symposium.

The conference also discussed administering effective doses and a need for additional research of Perchlozone in patients with HIV + tuberculosis co-infection.

At the conference, a new indication for use of Amizolid was announced – a combination therapy for pulmonary tuberculosis caused by MDR strains of Mycobacterium tuberculosis.